Pharmaceutical Strategic Outlook

CO-PROMOTES: A MARKETPLACE REALITY, BUT ARE THEY ALWAYS THE BEST FOR THE PRODUCT?
Annette Clancy, GlaxoSmithKline: Head, Transactions & Alliance Management, Worldwide Business Development
Barbara Yanni, Merck & Co.: VP & Chief Licensing Officer
Lessons from the Lilly/Cialis Deal
Leonard M. Blum, Icos: SVP, Sales and Marketing

DEALMAKING TRENDS
Roger Longman, Windhover Information: Managing Partner

THE $100 MILLION IND: THE NEW STRUCTURES AND VALUES FOR EARLY-STAGE COMPOUNDS
Early-stage Deal Valuations
Thomas R. Kassberg, InterMune: SVP, Corporate Development & Commercial Operations
Jeffrey Tong, Ph.D., Infinity & Discovery Partners: VP of Corporate and Product Development

OUT-LICENSING: FOUR STRUCTURES
Out-Partnering at Lilly & the Anthera Deal
Michael Johnson, Eli Lilly: Director, Corporate Business Development
Outlicensing a Portion of Pharma's Drug Development: The Drug Repositioning Model
Mark Gessler, Gene Logic Inc.: President & CEO
Accessing Pharma Assets—Without a Clawback
Michael A. Boss, Ph.D., MBA, Xanthus Pharmaceuticals: Chief Business Officer
Wyeth’s Recent Deal with Neurogen on Aplindore
Thomas Hofstaetter, Ph.D., Wyeth: Senior Vice President, Corporate Business Development

BUYING BIOTECHS: MODELS FOR M$A
Ally to Buy: the Domantis/GSK Deal
Robert Connelly, Domantis: CEO and Director

THE BIGGEST RNAi DEAL
The Views from the Buyer & Seller in the Biggest RNAi Deal Yet
Merv Turner, Ph.D., Merck: Senior Vice President, Worldwide Licensing and External Research
Howard W. Robin, Sirna Therapeutics, Inc.: President & CEO

DEALMAKING IN PERSONALIZED MEDICINE
The Effect of a Biomarker on Deal Valuation
K. Peter Hirth, Plexxikon: CEO
DeCoding Drug Discovery and Development
Kari Stefansson, DeCode: President and CEO
Multiple Indications and Nexavar: Original Intentions in the Bayer Deal … and What We’d Change the Next Time
Hollings Renton, Onyx Pharmaceuticals: CEO

PANEL DISCUSSION:
The Complexity of Dealmaking Around Multiple Indications
Moderated by Ben Bonifant, Campbell Alliance: Senior Practice Director

Edmund Harrigan
SVP Worldwide Licensing & Bus. Dev
Pfizer Inc.

Thomas Hofstaetter
SVP, Corporate Business Dev.
Wyeth

Annette Clancy
VP Business Development
GlaxoSmithKline

Leonard M. Blum
SVP, Sales & Marketing
Icos Corporation

Howard W. Robin
President & CEO
Sirna Therapeutics, Inc.

Hollings C. Renton
President, CEO & Chairman
Onyx Pharmaceuticals

Mervyn J. Turner
SVP, WW Lic. & External Research
Merck Research Laboratories

Mark D. Gessler
President, CEO & Chairman
Gene Logic Inc.

Joshua Salisbury
VP, Corp. Bus. Dev.
Eli Lilly & Co

Michael F. Johnson
Dir., Corp. Bus. Dev.
Eli Lilly & Co

Kari Stefansson
President & CEO
deCODE genetics

Ben Bonifant
Vice President, Business Development Campbell Alliance Group

Marshall Smith
Goldman Sachs & Co.

John Goddard
SVP, Strat. Planning & Bus. Development
AstraZeneca

Thomas R. Kassberg
SVP, Corp. Dev. & Commerc. Oper.
InterMune Pharmaceuticals Inc

Robert T. Connelly
CEO & Director
Domantis

Peter Hirth
Founder and Chief Executive Officer
Plexxikon Inc.

Jeffrey T. Tong
VP of Corporate and Product Development
Infinity Pharmaceuticals Inc.

Michael A. Boss
Chief Business Officer
Xanthus Pharmaceuticals, Inc.

Roger Longman
Managing Partner
Windhover Information